AKAO 2018 Proxy Statement

36 EXECUTIVE COMPENSATION TABLES 2017 Summary Compensation Table The following table sets forth total compensation paid to our named executive officers for the fiscal years ended December 31, 2017, December 31, 2016 and December 31, 2015, to the extent named executive officer was a named executive officer for such fiscal year. Name and Principal Position Year Salary ($) Option Awards (1) ($) Stock Awards (1) ($) Non-Equity Incentive Plan Compensation (2) ($) All Other Compensation ($) Total ($) Kenneth J. Hillan, M.B., Ch.B., 2017 452,400 3,263,200 938,528 158,340 10,600 (3) 4,823,068 Chief Executive Officer 2016 435,000 364,087 105,996 326,000 10,600 1,241,683 2015 425,000 732,562 336,168 170,000 7,950 1,671,680 Blake Wise, 2017 450,000 1,631,600 469,264 141,750 9,000 (3) 2,701,614 President and Chief Operating Officer 2016 410,000 89,280 23,166 225,000 9,000 756,446 2015 102,500 594,474 219,750 — — 916,724 Tobin C. Schilke, Chief Financial Officer 2017 365,000 1,027,908 316,753 84,000 9,000 (3) 1,802,661 Lee Swem, Ph.D., Chief Scientific Officer 2017 320,000 815,800 234,632 79,000 9,000 (3) 1,458,432 Gary Loeb, General Counsel and Chief Compliance Officer 2017 360,000 — — 89,000 9,000 (3) 458,000 Ian Friedland, M.D., 2017 88,896 481,506 (5) 106,838 (5) — 677,402 (4) 1,354,642 Former Chief Medical Officer 2016 422,500 149,300 45,907 200,000 10,600 828,307 2015 410,200 381,538 176,700 120,000 7,950 1,096,388 (1) Amounts shown represent the grant date fair value of stock options or restricted stock units granted, as calculated in accordance with ASC Topic 718. The grant date fair value of stock options with a market condition is based on the probable outcome of such condition; no maximum value applies. See Note 10 of the financial statements included in our Annual Report on Form 10-K filed February 27, 2018 for the assumptions used in calculating these amounts. (2) The amounts reported in the Non-Equity Incentive Plan Compensation column represent the annual cash performance-based bonuses earned by our NEOs pursuant to the achievement of certain corporate performance objectives and individual performance. The amounts listed for 2017 were paid to the named executive officers in early 2018. Please see the descriptions of the 2017 annual bonus program in “Compensation Discussion and Analysis - Annual Performance-Based Incentive Compensation” above. (3) Amounts represent the Company’s matching contribution under its 401(k) plan. (4) Amounts represent payments received by Dr. Friedland pursuant to his transition and separation agreement and consulting agreement with the Company, including (i) $319,800, representing nine months of his base salary; (ii) $5,697, representing nine months of reimbursement for COBRA premiums; (iii) $5,000 representing the Company’s matching contribution under its 401(k) plan; and (iv) $346,905, representing consulting fees paid to Planet Pharma, LLC and Friedland Strategic Consulting, LLC for Dr. Friedland’s services to the Company. (5) Amounts for Dr. Friedland represent the incremental fair value of stock and option awards modified pursuant to the transition and separation agreement entered into with him. See Note 10 of the financial statements included in our Annual Report on Form 10-K filed February 27, 2018 for the assumptions used in calculating these amounts